1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. HEPATITIS B VACCINE MARKET BY TYPE
5.1. Introduction
5.2. Combination Vaccines
5.3. Single Antigen Hepatitis B Vaccines
6. HEPATITIS B VACCINE MARKET BY TARGET POPULATION
6.1. Introduction
6.2. Infants
6.3. Children
6.4. Adults
6.5. High-Risk Population
7. HEPATITIS B VACCINE MARKET BY END-USER
7.1. Introduction
7.2. Hospitals
7.3. Clinics
7.4. Others
8. HEPATITIS B VACCINE MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Novartis AG
10.2. CSL Ltd
10.3. Dyanax Technologies
10.4. Beijing Minhai Biotechnology
10.5. Emergent Biosolutions
10.6. GlaxoSmithKline Biologics
10.7. Merck & Co. Inc.
10.8. Pfizer Inc.
10.9. Sanofi Pasteur
10.10. Serum Institute of India
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES